The 11 most recent market catalysts affecting $CC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Chemours Stock Trading Higher Today?
Chemours, DuPont, and Corteva have settled a major PFAS-related litigation in North Carolina for $455 million. This is a significant positive for Chemours (CC) as its portion of th…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Chemours, DuPont De Nemours And Corteva Reach Settlement State Of North Carolina And 11 Local Entities; Overall Settlement Payments Total $455M Over 15 Years, With Chemours' 50% Share Of Payments Of ~$180M On NPV Basis Covered By Existing Accruals
Chemours, DuPont, and Corteva have settled a major PFAS contamination lawsuit with North Carolina and 11 local entities for $455 million, payable over 15 years. This is a significa…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $15
JP Morgan's analyst Jeffrey Zekauskas maintained a 'Neutral' rating on Chemours but notably reduced the price target from $22 to $15. This action signals a more conservative valuat…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $18
BMO Capital's analyst John McNulty reiterated an 'Outperform' rating on Chemours (CC) but simultaneously reduced the price target from $26 to $18. This action signals that while th…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Chemours shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $29 to $18.
This downgrade represents a significant corporate catalyst for Chemours (CC), directly impacting its stock price negatively. The shift from 'Buy' to 'Neutral' by a major investment…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 65
UBS Downgrades Chemours to Neutral, Lowers Price Target to $18
UBS analyst Joshua Spector downgraded Chemours (CC) from a 'Buy' to a 'Neutral' rating and slashed the price target from $29 to $18. This significant revision reflects a diminished…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Chemours Launches Of Opteon ZE And Opteon 515B For Stationary Chiller Applications Required By Data Centers
Chemours (CC) has launched two new low-GWP refrigerants, Opteon ZE and Opteon 515B, specifically designed for stationary chiller applications in data centers. This is a strategic m…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $22
RBC Capital's analyst Arun Viswanathan has maintained an 'Outperform' rating on Chemours (CC) but lowered the price target from $26 to $22. This action signals a recalibration of t…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Chemours shares are trading lower after the company reported worse-than-expected Q2 sales results. Also, the company issued Q3 sales guidance below estimates.
This headline represents a significant corporate catalyst for Chemours (CC), directly impacting its share price negatively. The combination of past underperformance (Q2 sales miss)…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Chemours shares are trading lower after the company reported worse-than-expected Q2 sales results. Also, the company issued Q3 sales guidance below estimates.
This headline is a significant corporate catalyst for Chemours (CC), directly impacting its stock price due to poor financial performance and a weak outlook. The worse-than-expecte…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Chemours Q2 Adj. EPS $0.42, Inline, Sales $1.591B Miss $1.654B Estimate
Chemours' Q2 earnings per share met analyst consensus, which is a positive sign for profitability. However, the company's sales missed estimates by 3.81% and also decreased year-ov…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.